Helius Medical Technologies Gains New Reimbursement for PoNS Device

NEWTOWN, Pa., May 12, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) has received reimbursement approval for its Portable Neuromodulation Stimulator (PoNS®) from United Healthcare, marking a significant milestone as the second major healthcare provider after Anthem to offer coverage for the device.

The approved reimbursement totals $18,100, which includes the patient co-payment. This amount reflects the typical adjusted price for out-of-network services. “This additional claim approval from a second major healthcare provider validates the clinical need and benefits of PoNS,” said Dane Andreeff, President and CEO of Helius Medical Technologies.

Andreeff emphasized that the received pricing would facilitate constructive discussions with additional payors. The company is actively pursuing broader commercial coverage and reimbursement strategies to enhance access to the PoNS device for patients, especially those dealing with multiple sclerosis (MS).

The PoNS device, which is a non-invasive therapy that provides electrical stimulation through a mouthpiece, is designed to assist with balance and gait deficits. It is indicated for adults with mild-to-moderate symptoms of MS and is intended to be used alongside supervised therapeutic exercise programs.

Helius Medical Technologies aims to continue its growth strategy while expanding its market presence in the neurotechnology sector, ensuring that more patients can benefit from this advanced therapeutic option.

With discussions of patient access proceeding, Andreeff stated, “We are pleased with this progress in our efforts to support more MS patients.”